A Randomised, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of VR942 in Healthy Subjects and Repeated Doses in Mild Asthmatics
Phase of Trial: Phase I
Latest Information Update: 24 May 2017
At a glance
- Drugs VR 942 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors Vectura
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 22 Nov 2016 According to a Vectura Group plc media release, the company plans to present results from this trial at ehe American Thoracic Society in May 2017.
- 03 Jun 2016 According to a Vectura media release, detailed study outcomes will be presented at a future scientific conference.